Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial

Fig. 3

Response rates of SR-aGVHD after 4 weeks of treatment. Patients in the MSC group (using MSCs plus basiliximab) achieved superior responses compared to outcomes in the control group (using basiliximab alone) stratified according to a all enrolled patients, b patients with grade 3–4 SR-aGVHD, c patients with skin SR-GVHD, d patients with gut SR-GVHD, e patients with liver SR-GVHD, and f patients with SR-GVHD involving ≥2 organs

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us